financetom
Market
financetom
/
Market
/
Kivah Advisors says domestic investors continue to remain cautious; see value in beaten down midcaps
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Kivah Advisors says domestic investors continue to remain cautious; see value in beaten down midcaps
Nov 27, 2020 7:45 AM

Mithun Aswath, managing partner of Kivah Advisors on Friday said he believes that domestic investors continue to remain cautious. However, there is value in some of the beaten down midcap stocks.

He said, "The midcap space has still not reached all-time highs. You have seen the Nifty reach its all-time high, while the mid and small caps have still lagged behind. That is primarily also because we have not seen similar amount of flows into the mid and small cap fund area."

Aswath said he has invested in pharmaceuticals, technology, and some auto names. However, currently he likes the travel and retail space.

"Within the retail space one of the stocks that we have advised to clients recently is a company called Raymond which trades at a huge discount to its asset value at the current levels. As things have started to open up, maybe in this Diwali quarter, you will see revenue move back up for a company like Raymond," he said.

On Cera Sanitaryware, Aswath said, "The company is a leader in the sanitaryware, faucets, as well as tiles space. It is mainly in the former 2 categories and addresses tier-2 and tier-3 markets which have been less impacted by COVID. The last quarter was hit because of their own issues they had in their factories. But in the second half, we do think there could be a big recovery."

Disclaimer: The views and investment tips expressed by investment experts on CNBCTV18.com are their own and not that of the website or its management. CNBCTV18.com advises users to check with certified experts before taking any investment decisions.

Watch the video for more

(Edited by : Jomy Pullokaran)

First Published:Nov 27, 2020 4:45 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Top Midday Stories: Oracle Fiscal Q2 Results Miss Estimates; Boeing Resumes 737 MAX Production
Top Midday Stories: Oracle Fiscal Q2 Results Miss Estimates; Boeing Resumes 737 MAX Production
Dec 10, 2024
11:41 AM EST, 12/10/2024 (MT Newswires) -- All three major US stock indexes were up slightly in late-morning trading Tuesday, as market participants await the latest round of consumer price index data on Wednesday. In company news, Oracle (ORCL) reported fiscal Q2 non-GAAP earnings late Monday of $1.47 per share, up from $1.34 a year earlier but below the consensus...
US Equity Indexes Mixed in Midday Trading
US Equity Indexes Mixed in Midday Trading
Dec 10, 2024
12:23 PM EST, 12/10/2024 (MT Newswires) -- US equity indexes traded mixed, and government bond yields rose with the dollar amid caution in markets ahead of a tick-up expected in month-over-month headline inflation. The S&P 500, Nasdaq Composite and the Dow Jones Industrial Average stood little changed at 6,052.2, 19,736.5 and 44,418.7, respectively, after midday on Tuesday. Communication services and...
US Equity Indexes Steady as Treasury Yields, Dollar Advance Ahead of Pivotal Inflation Report
US Equity Indexes Steady as Treasury Yields, Dollar Advance Ahead of Pivotal Inflation Report
Dec 10, 2024
01:01 PM EST, 12/10/2024 (MT Newswires) -- US equity indexes traded steady as government bond yields rose and the dollar appreciated ahead of a tick-up anticipated in month-over-month headline inflation. The S&P 500 and the Dow Jones Industrial Average stood little changed at 6,057.5 and 44,421.9, respectively, after midday on Tuesday. The Nasdaq Composite climbed 0.2% to 19,780.1. The S&P...
Top Midday Gainers
Top Midday Gainers
Dec 10, 2024
01:05 PM EST, 12/10/2024 (MT Newswires) -- Chimerix ( CMRX ) plans to submit a new drug application before the end of the year for accelerated approval of dordaviprone to treat recurrent H3 K27M-mutant diffuse glioma. The stock price more than tripled Tuesday as intraday volume topped 153.7 million shares versus the daily average of almost 489,000. UniQure ( QURE...
Copyright 2023-2025 - www.financetom.com All Rights Reserved